|
WO2021078834A1
|
|
Chimeric acid-alpha glucosidase polypeptides and uses thereof
|
|
WO2021078833A1
|
|
Chimeric polypeptides and uses thereof
|
|
WO2021053124A1
|
|
Gene therapy expression system alleviating cardiac toxicity of fkrp
|
|
WO2021005176A1
|
|
Treatment of glycogen storage disease (gsd)
|
|
WO2020212626A1
|
|
Gene therapy of fibroblast growth factor 23 related hypophosphatemic diseases
|
|
WO2020208032A1
|
|
Hybrid promoters for muscle expression
|
|
WO2020193636A1
|
|
Production of large-sized quasidystrophins using overlapping aav vectors
|
|
WO2020127813A1
|
|
Expression cassettes for gene therapy vectors
|
|
WO2020079256A1
|
|
Modulation, monitoring and prediction of the immune response directed against aav gene therapy vectors
|
|
CA3107572A1
|
|
Mini-gde for the treatment of glycogen storage disease iii
|
|
EP3770264A1
|
|
Precise integration using nuclease targeted idlv
|
|
CA3093347A1
|
|
Hybrid recombinant adeno-associated virus serotype between aav9 and aavrh74 with reduced liver tropism
|
|
CA3086942A1
|
|
Hybrid regulatory elements
|
|
EP3685846A1
|
|
Use of thiostrepton or its derivatives for the treatment of genetic diseases linked to a protein conformational disorder
|
|
CN111246874A
|
|
Use of syncytin for targeted delivery of drugs and genes to regenerating muscle tissue
|
|
CN111225682A
|
|
Use of syncytin for targeted delivery of drugs and genes to lung tissue
|
|
CN111065741A
|
|
Treatment of spinal muscular atrophy
|
|
CN110944656A
|
|
Novel polynucleotides encoding human FKRP proteins
|
|
US2021095291A1
|
|
Antisense targeting dynamin 2 and use for the treatment of centronuclear myopathies and neuropathies
|
|
CA3053455A1
|
|
Treatment of glycogen storage disease iii
|
